Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 127
Filtrar
1.
Am J Case Rep ; 25: e943244, 2024 04 21.
Artículo en Inglés | MEDLINE | ID: mdl-38643357

RESUMEN

BACKGROUND Nephrogenic diabetic insipidus (NDI) poses a challenge in clinical management, particularly when associated with lithium ingestion. Non-selective non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used for the treatment of numerous diseases worldwide, including NDI. However, many studies have reported the diverse adverse effects of long-term use of non-selective NSAIDs. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a better drug to relieve pain and inflammation in terms of long-term safety and efficacy than non-selective NSAIDs. Nevertheless, there are few reports describing the effectiveness of celecoxib in treating NDI. CASE REPORT We report a case of a 46-year-old woman with schizophrenia who presented with severe hypernatremia and refractory polyuria due to lithium-induced NDI. Cessation of lithium ingestion and traditional treatments, including trichlormethiazide and desmopressin, yielded minimal improvement in her hypernatremia and polyuria. Her sodium level needed to be strictly controlled with the infusion of dextrose 5% in water. Given the safety of celecoxib, we decided to initiate celecoxib as the treatment of lithium-induced NDI instead of indomethacin. Notably, the introduction of celecoxib led to a substantial and sustained amelioration of polyuria and hypernatremia without any celecoxib-associated adverse effects. Even after transfer to another hospital, stability in serum sodium levels persisted with celecoxib. CONCLUSIONS We presented a case of lithium-induced NDI successfully treated with celecoxib, a selective COX-2 inhibitor. To the best of our knowledge, this is the first reported case of successful treatment of lithium-induced NDI with celecoxib, and suggests celecoxib is a viable therapeutic option warranting further exploration. Physicians should consider its use when faced with the challenging management of lithium-induced NDI.


Asunto(s)
Diabetes Insípida Nefrogénica , Diabetes Mellitus , Hipernatremia , Femenino , Humanos , Persona de Mediana Edad , Diabetes Insípida Nefrogénica/inducido químicamente , Diabetes Insípida Nefrogénica/tratamiento farmacológico , Litio/uso terapéutico , Celecoxib/uso terapéutico , Poliuria/inducido químicamente , Poliuria/tratamiento farmacológico , Hipernatremia/inducido químicamente , Hipernatremia/tratamiento farmacológico , Antiinflamatorios no Esteroideos/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico , Sodio
2.
Ann Parasitol ; 69(3-4): 115-118, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38423520

RESUMEN

Treatment of liver hydatid cysts is still in most cases surgical. To avoid the recurrence of hydatid cysts injection of scolicidal products inside the cystic cavity is an important step in the surgical procedure. Many scolicidal solutions are used. Hypertonic Saline Solution (HSS) is widely used by surgeons; however, there is a risk of hypertonic saline resorption and acute hypernatremia. Iatrogenic hypernatremia can be life-threatening. We report three cases of hypernatremia secondary to HSS injection for hydatid cyst disease treatment. The objective of this study was to discuss the clinical features, and treatment of this rare complication.


Asunto(s)
Abdomen Agudo , Equinococosis Hepática , Equinococosis , Echinococcus , Hipernatremia , Animales , Humanos , Hipernatremia/complicaciones , Hipernatremia/tratamiento farmacológico , Abdomen Agudo/complicaciones , Abdomen Agudo/tratamiento farmacológico , Equinococosis/cirugía , Equinococosis Hepática/complicaciones , Equinococosis Hepática/cirugía , Equinococosis Hepática/tratamiento farmacológico , Solución Salina Hipertónica/uso terapéutico
3.
Paediatr Drugs ; 25(5): 595-601, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37326929

RESUMEN

BACKGROUND: Experience with nasogastric administration of oral DDAVP [desamino-D-arginine-8-vasopressin] lyophilisate (ODL) for central diabetes insipidus (CDI) in disabled children with swallowing coordination difficulties is limited. OBJECTIVE: We aimed to assess the safety and efficacy of nasogastric use of ODL in disabled children with CDI. Time to serum sodium normalisation was compared with that of children with normal intellect and CDI treated with sublingual DDAVP. METHODS: Clinical, laboratory and neuroimaging characteristics were evaluated for 12 disabled children with CDI treated with ODL through nasogastric tube at Dr Behcet Uz Children's Hospital, Turkey, between 2012 and 2022. RESULTS: Six boys and six girls with a mean (±SD) age of 43 (± 40) months were evaluated. These children (mean [±SD] weight standard deviation score [SDS] - 1.2 ± 1.7; mean [±SD] height SDS - 1.3 ± 1.4) presented with failure to thrive, irritability, prolonged fever, polyuria and hypernatraemia (mean serum sodium 162 [±3.6] mEq/L). At diagnosis, mean serum and urine osmolality were 321 (± 14) mOsm/kg and 105 (± 7.8) mOsm/kg, respectively. Arginine vasopressin (AVP) levels were undetectable (< 0.5 pmol/L) at diagnosis in all patients. Nasogastric tube administration of DDAVP lyophilisate (120 µg/tablet) dissolved in water (10 mL) was commenced at a dose of 1-5 µg/kg/day in two divided doses together with controlled water intake to avoid hyponatraemia. The frequency and dose of DDAVP were titrated based on urine output and serum sodium concentration. Serum sodium declined at a rate of 0.11 ± 0.03 mEq/L/h and reached normal range in a mean duration of 174 ± 46.5 h. Serum sodium declined faster in children with normal intellect and CDI treated with sublingual DDAVP (1.28 ± 0.39 mEq/L/h; p = 0.0003). Three disabled children needed rehospitalisation because of hypernatraemia due to unintentional DDAVP omission by caregivers. No episode of hyponatraemia was observed. Weight gain and growth were normal during the median (± interquartile range) follow-up duration of 32 ± 67 months. CONCLUSIONS: Nasogastric administration of oral DDAVP lyophilised formulation was safe and effective in the treatment of CDI in disabled children in this small retrospective series.


Asunto(s)
Diabetes Insípida Neurogénica , Diabetes Mellitus , Niños con Discapacidad , Hipernatremia , Hiponatremia , Masculino , Niño , Femenino , Humanos , Preescolar , Diabetes Insípida Neurogénica/tratamiento farmacológico , Diabetes Insípida Neurogénica/etiología , Desamino Arginina Vasopresina/efectos adversos , Estudios Retrospectivos , Hipernatremia/tratamiento farmacológico , Hiponatremia/tratamiento farmacológico , Hiponatremia/etiología , Sodio/uso terapéutico , Diabetes Mellitus/tratamiento farmacológico
5.
J Matern Fetal Neonatal Med ; 35(25): 6338-6345, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33879015

RESUMEN

BACKGROUND AND OBJECTIVES: The use of hypotonic fluids as maintenance therapy in the neonatal population has been in practice for a long time, but there is a lack of evidence for the choice of this fluid in neonates. This study compared isotonic (sodium chloride, 0.9%, and dextrose, 5%) versus hypotonic (sodium chloride, 0.15%, and dextrose, 5%) intravenous fluid for maintenance fluid therapy in neonates more than or equal to 34 weeks of gestational age. METHODS: In this triple-blind randomized clinical trial, we recruited 60 neonates admitted to a neonatal intensive care unit of a tertiary care children's hospital from June 2017 through May 2018 with normal baseline serum sodium levels, anticipated to require intravenous maintenance fluids for 24 hours or longer (intention-to-treat analyses). Patients were randomized to receive isotonic or hypotonic intravenous fluid at maintenance rates for 72 hours. The primary outcome was the incidence of hyponatremia (defined as serum sodium <135mEq/L) at 24 hours in both groups. The secondary outcomes were incidence of hypernatremia at 24 hours (defined as serum sodium >145 mEq/L), the incidence of hypo and hypernatremia at 48 and 72 hours, mean serum sodium at 24, 48, and 72 hours, rate of change of serum sodium during the study period, mean serum osmolality at the end of the study period, the absolute difference in osmolality during the study period, the absolute difference in weight during the study period and edema during the study period. RESULTS: Of 60 enrolled neonates, 31 received isotonic fluids and 29 received hypotonic fluids. Three patients in the hypotonic group developed hyponatremia and none in isotonic group at 24 h (RR = 0.13; 95% CI = 0.007 - 2.485; p = .106). Fourteen neonates developed hypernatremia in the isotonic group and one in hypotonic group at 24 h (RR = 13.09; 95% CI = 1.83 - 93.4; p = .0001). CONCLUSIONS: Our study results do not support the hypothesis that isotonic fluid is superior to hypotonic fluid in reducing the proportion of neonates developing hyponatremia after 24 hours of intravenous fluid therapy. The proportion of neonates developing hypernatremia is significantly higher after using isotonic fluid for maintenance therapy. TRIAL REGISTRATION CTRI/2017/05/008585.


Asunto(s)
Hipernatremia , Hiponatremia , Niño , Recién Nacido , Humanos , Soluciones Hipotónicas , Hiponatremia/etiología , Hipernatremia/tratamiento farmacológico , Hipernatremia/etiología , Soluciones Isotónicas , Cloruro de Sodio , Edad Gestacional , Infusiones Intravenosas , Fluidoterapia/efectos adversos , Sodio , Glucosa
8.
J Postgrad Med ; 67(1): 36-38, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33533750

RESUMEN

Glyphosate is the most commonly used broad-spectrum, non-selective herbicide in the world. The toxicity is supposed to be due to uncoupling of oxidative phosphorylation and the surfactant polyoxyethylene amine (POEA)- mediated cardiotoxicity. Clinical features of this herbicide poisoning are varied, ranging from asymptomatic to even death. There is no antidote and aggressive supportive therapy is the mainstay of treatment for glyphosate poisoning. We present a 69-year-old female patient with suicidal consumption of around 500 ml of Glycel®. Initially, gastric lavage was done and intravenous fluids were given. Within two hours of presentation, the patient developed respiratory distress needing intubation, hypotension needing vasopressor support, and severe lactic acidosis. She also developed acute respiratory distress syndrome, hypokalemia, hypernatremia, and aspiration pneumonia. Our patient was critically ill with multiple poor prognostic factors, but with timely aggressive supportive management, the patient gradually recovered.


Asunto(s)
Glicina/análogos & derivados , Herbicidas/envenenamiento , Hipernatremia/etiología , Hipopotasemia/etiología , Neumonía por Aspiración/etiología , Síndrome de Dificultad Respiratoria/etiología , Anciano , Cefamandol/administración & dosificación , Cefamandol/análogos & derivados , Cefamandol/uso terapéutico , Cefoperazona/administración & dosificación , Cefoperazona/uso terapéutico , Clindamicina/administración & dosificación , Clindamicina/uso terapéutico , Suplementos Dietéticos , Femenino , Glicina/envenenamiento , Humanos , Hipernatremia/tratamiento farmacológico , Hipopotasemia/tratamiento farmacológico , Neumonía por Aspiración/tratamiento farmacológico , Potasio/administración & dosificación , Potasio/uso terapéutico , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Intento de Suicidio , Sulbactam/administración & dosificación , Sulbactam/uso terapéutico , Resultado del Tratamiento , Glifosato
9.
J. bras. nefrol ; 42(1): 106-112, Jan.-Mar. 2020. tab, graf
Artículo en Inglés, Portugués | LILACS | ID: biblio-1098343

RESUMEN

Abstract Hypernatremia is a common electrolyte problem at the intensive care setting, with a prevalence that can reach up to 25%. It is associated with a longer hospital stay and is an independent risk factor for mortality. We report a case of hypernatremia of multifactorial origin in the intensive care setting, emphasizing the role of osmotic diuresis due to excessive urea generation, an underdiagnosed and a not well-known cause of hypernatremia. This scenario may occur in patients using high doses of corticosteroids, with gastrointestinal bleeding, under diets and hyperprotein supplements, and with hypercatabolism, especially during the recovery phase of renal injury. Through the present teaching case, we discuss a clinical approach to the diagnosis of urea-induced osmotic diuresis and hypernatremia, highlighting the utility of the electrolyte-free water clearance concept in understanding the development of hypernatremia.


Resumo A hipernatremia é um distúrbio eletrolítico comum no ambiente de terapia intensiva, com uma prevalência que pode chegar a 25%. Está associada a maior tempo de internação hospitalar e é um fator de risco independente para a mortalidade. Este relato ilustra um caso de hipernatremia de origem multifatorial no ambiente de terapia intensiva. Destacaremos o papel da diurese osmótica por geração excessiva de ureia, uma causa de hipernatremia pouco conhecida e subdiagnosticada. Este cenário pode estar presente em pacientes em uso de elevadas doses de corticoides, com sangramento gastrointestinal, em uso de dietas e suplementos hiperproteicos e estado de hipercatabolismo, especialmente durante a fase de recuperação de injúria renal. A seguir, discutiremos uma abordagem clínica para o diagnóstico da hipernatremia secundária à diurese osmótica induzida por ureia, destacando a importância do conceito de clearance de água livre de eletrólitos nesse contexto.


Asunto(s)
Humanos , Femenino , Anciano , Urea/orina , Urea/sangre , Cuidados Críticos/métodos , Diuresis , Hipernatremia/diagnóstico , Potasio/orina , Potasio/sangre , Sodio/orina , Sodio/sangre , Estudios de Seguimiento , Resultado del Tratamiento , Enfermedad Crítica , Nutrición Enteral/métodos , Corticoesteroides/administración & dosificación , Dieta con Restricción de Proteínas/métodos , Hipernatremia/tratamiento farmacológico , Unidades de Cuidados Intensivos
10.
J Bras Nefrol ; 42(1): 106-112, 2020 Mar.
Artículo en Portugués, Inglés | MEDLINE | ID: mdl-31063175

RESUMEN

Hypernatremia is a common electrolyte problem at the intensive care setting, with a prevalence that can reach up to 25%. It is associated with a longer hospital stay and is an independent risk factor for mortality. We report a case of hypernatremia of multifactorial origin in the intensive care setting, emphasizing the role of osmotic diuresis due to excessive urea generation, an underdiagnosed and a not well-known cause of hypernatremia. This scenario may occur in patients using high doses of corticosteroids, with gastrointestinal bleeding, under diets and hyperprotein supplements, and with hypercatabolism, especially during the recovery phase of renal injury. Through the present teaching case, we discuss a clinical approach to the diagnosis of urea-induced osmotic diuresis and hypernatremia, highlighting the utility of the electrolyte-free water clearance concept in understanding the development of hypernatremia.


Asunto(s)
Cuidados Críticos/métodos , Diuresis , Hipernatremia/diagnóstico , Urea/sangre , Urea/orina , Corticoesteroides/administración & dosificación , Anciano , Enfermedad Crítica , Dieta con Restricción de Proteínas/métodos , Nutrición Enteral/métodos , Femenino , Estudios de Seguimiento , Humanos , Hipernatremia/dietoterapia , Hipernatremia/tratamiento farmacológico , Unidades de Cuidados Intensivos , Potasio/sangre , Potasio/orina , Sodio/sangre , Sodio/orina , Resultado del Tratamiento
11.
Curr Opin Crit Care ; 25(2): 132-137, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30855321

RESUMEN

PURPOSE OF REVIEW: To describe the pathophysiology and pharmacotherapy of dysnatremia in neurocritical care patients. RECENT FINDINGS: Sodium disorders may affect approximately half of the neurocritical care patients and are associated with worse neurological outcome and increased risk of death. Pharmacotherapy of sodium disorders in neurocritical care patients may be challenging and is guided by a careful investigation of water and sodium balance. SUMMARY: In case of hyponatremia, because of excessive loss of sodium, fluid challenge with isotonic solution, associated with salt intake is the first-line therapy, completed with mineralocorticoids if needed. In case of hyponatremia because of SIADH, fluid restriction is the first-line therapy followed by urea if necessary. Hypernatremia should always be treated with hypotonic solutions according to the free water deficit, associated in case of DI with desmopressin. The correction speed should take into consideration the symptoms associated with dysnatremia and the rapidity of the onset.


Asunto(s)
Hipernatremia , Hiponatremia , Enfermedades del Sistema Nervioso , Desequilibrio Hidroelectrolítico , Cuidados Críticos , Humanos , Hipernatremia/tratamiento farmacológico , Hiponatremia/tratamiento farmacológico , Soluciones Hipotónicas , Enfermedades del Sistema Nervioso/complicaciones , Sodio
12.
Crit Care Clin ; 35(2): 187-200, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-30784603

RESUMEN

Diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion lie at opposite ends of the spectrum of disordered renal handling of water. Whereas renal retention of water insidiously causes hypotonic hyponatremia in syndrome of inappropriate antidiuretic hormone secretion, diabetes insipidus may lead to free water loss, hypernatremia, and volume depletion. Hypernatremia and hyponatremia are associated with worse outcomes and longer intensive care stays. Moreover, pathologies causing polyuria and hyponatremia in patients in intensive care may be multiple, making diagnosis challenging. We provide an approach to the diagnosis and management of these conditions in intensive care patients.


Asunto(s)
Fármacos Antidiuréticos/uso terapéutico , Cuidados Críticos/normas , Desamino Arginina Vasopresina/uso terapéutico , Diabetes Insípida/tratamiento farmacológico , Hipernatremia/tratamiento farmacológico , Hiponatremia/tratamiento farmacológico , Síndrome de Secreción Inadecuada de ADH/tratamiento farmacológico , Diabetes Insípida/diagnóstico , Diabetes Insípida/fisiopatología , Femenino , Humanos , Hipernatremia/diagnóstico , Hiponatremia/diagnóstico , Síndrome de Secreción Inadecuada de ADH/diagnóstico , Síndrome de Secreción Inadecuada de ADH/fisiopatología , Masculino , Guías de Práctica Clínica como Asunto , Equilibrio Hidroelectrolítico/efectos de los fármacos
14.
Arch Pediatr ; 25(8): 480-484, 2018 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-30361085

RESUMEN

CONTEXT: Central diabetes insipidus (CDI) is a rare disease during the neonatal period, making it diagnosis difficult and delaying medical treatment. CASE REPORT: We report here a case of a premature infant born at 26 weeks gestation who, during his 1st month of life, presented persistent hypernatremia with polyuria despite increased fluid supply and low sodium intake. CDI diagnosis was suspected and then confirmed by the therapeutic test with vasopressin analog, in its oral form. Electrolyte disorders were normalized after treatment, which allowed normal weight and height growth with standard fluid supply. Biological and radiological tests were all normal; this CDI was considered idiopathic. CONCLUSION: Persistent hypernatremia with excessive diuresis should alert to CDI diagnosis.


Asunto(s)
Diabetes Insípida Neurogénica/diagnóstico , Desamino Arginina Vasopresina/uso terapéutico , Diabetes Insípida Neurogénica/tratamiento farmacológico , Humanos , Hipernatremia/tratamiento farmacológico , Hipernatremia/etiología , Recien Nacido Extremadamente Prematuro , Recién Nacido , Masculino
15.
J Clin Anesth ; 37: 52-54, 2017 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-28235528

RESUMEN

We describe the first case of severe hypernatremia associated to laparoscopic surgery for hydatid cyst in an adult patient after the use of hypertonic saline solution with complete resolution. Severe hypernatremia is an unusual fact at the immediate postoperative period but may have fatal consequences for the patient and need immediate action. The patient reached a serum sodium concentration of 179 mmol/L without adverse effects after 6 days of treatment. Laparoscopy could play a crucial role in Na+ absorption due to high intraabdominal pressure caused by the pneumoperitoneum and its limitations to avoid peritoneal absorption of hypertonic saline solution. The relation between this surgical technique and the severe complication is discussed. More experience is needed in terms of safety for the patient.


Asunto(s)
Colecistectomía Laparoscópica/efectos adversos , Equinococosis Hepática/cirugía , Equinococosis/cirugía , Hipernatremia/complicaciones , Neumoperitoneo Artificial/efectos adversos , Solución Salina Hipertónica/efectos adversos , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/uso terapéutico , Profilaxis Antibiótica/métodos , Equinococosis/diagnóstico por imagen , Equinococosis Hepática/diagnóstico por imagen , Efedrina/administración & dosificación , Efedrina/uso terapéutico , Femenino , Fentanilo/administración & dosificación , Fentanilo/uso terapéutico , Glucosa/administración & dosificación , Glucosa/uso terapéutico , Humanos , Hidrocortisona/administración & dosificación , Hidrocortisona/uso terapéutico , Hiperglucemia/sangre , Hiperglucemia/tratamiento farmacológico , Hipernatremia/sangre , Hipernatremia/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/uso terapéutico , Soluciones Hipotónicas/administración & dosificación , Soluciones Hipotónicas/uso terapéutico , Infusiones Intravenosas , Insulina/administración & dosificación , Insulina/uso terapéutico , Imagen por Resonancia Magnética , Persona de Mediana Edad , Hipotonía Muscular/tratamiento farmacológico , Hipotonía Muscular/etiología , Dolor Postoperatorio/tratamiento farmacológico , Periodo Posoperatorio , Solución Salina Hipertónica/administración & dosificación , Sodio/administración & dosificación , Sodio/uso terapéutico , Vasoconstrictores/administración & dosificación , Vasoconstrictores/uso terapéutico
17.
J Crit Care ; 38: 225-230, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27984823

RESUMEN

PURPOSE: Thiazides are suggested as a treatment for intensive care unit (ICU)-acquired hypernatremia (IAH). The primary aim of the study was reducing serum sodium concentration (sNa) in patients with IAH with hydrochlorothiazide (HCT) in comparison to placebo. Secondary end points were a difference in urine sodium concentration (uNa) and duration of severe IAH. MATERIALS: A monocentric, double-blind, placebo-controlled trial was conducted in 50 patients with IAH and urine potassium + uNa less than sNa in a spot urine sample. Patients were randomized to HCT 25 mg or placebo 1 qd for maximal 7 days. Patients on renal replacement therapy, on medication inducing diabetes insipidus, or with recent use of diuretics were excluded. IAH was defined as sNa of at least 143 mmol/L. RESULTS: At baseline, sNa and uNa were comparable between groups. During the study period, sNa decreased significantly with median 4 mmol/L in both groups, with no significant difference between groups (P=.32). Median uNa increased significantly in both groups (46 [16-86] mmol/L in the HCT-group; 20 [10-66]mmol/L in the placebo group), with no difference between groups (P=.34). Median duration of sNa of at least 145 mmol/L was 3 days in both groups (P=.91). CONCLUSION: HCT 25 mg 1 qd did not significantly affect sNa or uNa in patients with IAH.


Asunto(s)
Hidroclorotiazida/uso terapéutico , Hipernatremia/tratamiento farmacológico , Inhibidores de los Simportadores del Cloruro de Sodio/uso terapéutico , Anciano , Cuidados Críticos , Enfermedad Crítica , Método Doble Ciego , Femenino , Humanos , Hidroclorotiazida/administración & dosificación , Hipernatremia/sangre , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Países Bajos , Estudios Prospectivos , Inhibidores de los Simportadores del Cloruro de Sodio/administración & dosificación , Resultado del Tratamiento
18.
Georgian Med News ; (Issue): 12-16, 2016 Nov.
Artículo en Ruso | MEDLINE | ID: mdl-28009309

RESUMEN

The article presents the analysis of the intensive therapy through the correction of persistent hypernatremia in neurosurgical patients after removal of brain tumors. The aim of this work was to evaluate the effectiveness of Sterofundin in the framework of complex therapy of hypernatremia in neurosurgical patients after removal of brain tumors. We analyzed the dynamics of the concentrations of sodium, potassium, chorus of the plasma, anion gap and buffer bases in the postoperative period of these patients. For obtaining reliable results, the patients were divided into groups according to the nature of the treatment: Sterofundin and symptomatic correction of hypotonic solution of sodium chloride, saluretic and Verospiron respectively. In a comparison between the groups, a distinct difference in the speed of regression of hypernatremia and durability of the achieved effect was observed. In case of treatment with Sterofundin there was a significant decrease of hypernatremia by the end of the second day of the postoperative period without tendency to re-raise. The prevalence of hypotonic solutions of sodium chloride and potassium-sparing saluretics in intensive care allowed reducing the sodium concentration non-persistently to the fourth day on the background of significant fluctuations in its concentration. The use of Sterofundin in complex therapy of electrolyte disturbances, particularly of hypernatremia in neurosurgical patients after removal of brain tumors, is reflected in the form of significant regression of increased sodium concentration in plasma compared with the method of use "hypotonic" hemodilution, saluretics and potassium-sparing diuretics.


Asunto(s)
Adenoma/metabolismo , Neoplasias Encefálicas/metabolismo , Hipernatremia/tratamiento farmacológico , Complicaciones Posoperatorias/tratamiento farmacológico , Desequilibrio Ácido-Base/tratamiento farmacológico , Desequilibrio Ácido-Base/etiología , Adenoma/patología , Adenoma/cirugía , Adulto , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/cirugía , Femenino , Humanos , Hipernatremia/etiología , Hipotálamo/patología , Masculino , Procedimientos Neuroquirúrgicos/efectos adversos , Compuestos Orgánicos/uso terapéutico , Hipófisis/patología , Complicaciones Posoperatorias/etiología , Estudios Retrospectivos , Desequilibrio Hidroelectrolítico/tratamiento farmacológico , Desequilibrio Hidroelectrolítico/etiología
20.
J Crit Care ; 33: 200-6, 2016 06.
Artículo en Inglés | MEDLINE | ID: mdl-26948252

RESUMEN

BACKGROUND: Fluid and sodium overload are a common problem in critically ill patients. Frusemide may result in diuresis in excess of natriuresis. The addition of indapamide may achieve a greater natriuresis, and also circumvent some of the problems associated with frusemide. The objective of this study was to examine the effect of adding indapamide to frusemide on diuresis, natriuresis, creatinine clearance and serum electrolytes. METHODS: Fluid overloaded ICU patients were randomised to either intravenous frusemide (Group F) or intravenous frusemide and enteral indapamide (Group F + I). Comprehensive exclusion criteria were applied to address confounders. 24 hour urine was analysed for electrolytes and creatinine. Serum electrolytes were measured before and 24 hours after administration of diuretics. RESULTS: Forty patients (20 in each group) were included in the study. The groups were similar in their baseline characteristics. Over the 24 h study period, patients in Group F + I, had a larger natriuresis (P = 0.01), chloride loss (P = 0.01) and kaliuresis (P = 0.047). Patients in Group F + I also had a greater 24 hour urinary creatinine clearance (P = 0.01). The 24 hour urine volume and fluid balance was similar between the groups. Patients in Group F had an increase in serum sodium (P = 0.04), while patients in Group F + I had a decrease in both serum chloride (P = 0.01) and peripheral oedema (P < 0.001) during the study duration. CONCLUSION: In fluid overloaded ICU patients, addition of indapamide to frusemide led to a greater natriuresis and creatinine clearance. Such a strategy might be utilised in optimising sodium balance in ICU patients.


Asunto(s)
Diuréticos/uso terapéutico , Furosemida/uso terapéutico , Hipernatremia/tratamiento farmacológico , Indapamida/uso terapéutico , Anciano , Anciano de 80 o más Años , Creatinina/sangre , Cuidados Críticos , Diuresis/efectos de los fármacos , Diuréticos/administración & dosificación , Diuréticos/farmacología , Quimioterapia Combinada , Femenino , Furosemida/administración & dosificación , Furosemida/farmacología , Humanos , Hipernatremia/sangre , Hipernatremia/orina , Indapamida/administración & dosificación , Indapamida/farmacología , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Natriuresis/efectos de los fármacos , Estudios Prospectivos , Sodio/farmacología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA